Quantcast
Home > Quotes > AMPH
AMPH

Amphastar Pharmaceuticals, Inc. Common Stock (AMPH) Quote & Summary Data

$20.995
*  
0.175
0.84%
Get AMPH Alerts
*Delayed - data as of Jun. 20, 2019 11:48 ET  -  Find a broker to begin trading AMPH now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    AMPH Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 20.98 / $ 21.01
1 Year Target
25
Today's High / Low
$ 21.30 / $ 20.93
Share Volume
23,038
50 Day Avg. Daily Volume
166,163
Previous Close
$ 20.82
52 Week High / Low
$ 25.43 / $ 15.0407
Market Cap
988,137,422
P/E Ratio
419.9
Forward P/E (1y)
99.14
Earnings Per Share (EPS)
$ 0.05
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.07

Intraday Chart

Shares Traded

Share Volume:
23,038
50 Day Avg. Daily Volume:
166,163

P/E Ratio

P/E Ratio:
419.9
Forward P/E (1y):
99.14
Earnings Per Share (EPS):
$ 0.05

Trading Range

The current last sale of $20.995 is 39.59% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 21.30 $ 25.43
 Low: $ 20.93 $ 15.0407

Company Description (as filed with the SEC)

We are a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API, products. We currently manufacture and sell over 20 products. In November 2018, the Food and Drug Administration, or FDA, granted over-the-counter approval of our New Drug Application, or NDA, for Primatene┬« Mist in a new CFC-free formulation. We began selling Primatene┬« Mist in the fourth quarter of 2018. We are currently developing a portfolio of 15 generic abbreviated new drug applications, or ANDAs, three biosimilar product candidates and five proprietary product candidates, which are in various stages of development and targets a variety of indications. Five ANDAs and one NDA are currently on file with the FDA.  ... More ...  



Risk Grade

Where does AMPH fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 20.98
Open Date:
Jun. 20, 2019
Close Price:
$ 20.82
Close Date:
Jun. 19, 2019


Consensus Recommendation

Analyst Info